




Figure 1A




Figure 1B




Figure 1C




Figure 2A




Figure 2B




Figure 2C




Figure 3A




Figure 3B




Figure 3C




Figure 3D

Figure 4

NK cells “armed” / not washed




Figure 4A




Figure 4B

Armed NK cells after 24 h




Figure 4C




Figure 4D




Figure 5A




Figure 5B

Figure 5C




Figure 6A




Figure 6B




Figure 7A




Figure 7B




Figure 7C




Figure 7D

13/15



Figure 8




Figure 9A




Figure 9B




Figure 10

Efficacy of *ex vivo* armed NK cells with a recombinant Fc SDH rituximab on B-lymphoma primary cancer cells




Figure 11